Placebo effects in treating migraine and other headaches

Current Opinion in Investigational Drugs

Volumn 11, Issue 7, 2010, Pages 735-739

  Diener, Hans Christoph ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; BISOPROLOL; BOTULINUM TOXIN; CYCLANDELATE; ELETRIPTAN; MAGNESIUM; METOCLOPRAMIDE; NARATRIPTAN; PLACEBO; PROPRANOLOL; RIZATRIPTAN; SUMATRIPTAN; VALPROIC ACID; ZOLMITRIPTAN;

ACUPUNCTURE; CLINICAL TRIAL; CULTURAL FACTOR; HUMAN; MIGRAINE; PLACEBO EFFECT; PROPHYLAXIS; REVIEW; ADOLESCENT; ADULT; CHILD; CLINICAL TRIAL (TOPIC); HEADACHE; MIGRAINE DISORDERS;

ADOLESCENT; ADULT; CHILD; CLINICAL TRIALS AS TOPIC; HEADACHE; HUMANS; MIGRAINE DISORDERS; PLACEBO EFFECT; PLACEBOS;

EID: 77954122035     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Kupers R, Faymonville ME, Laureys S: The cognitive modulation of pain: Hypnosis- and placebo-induced analgesia. Prog Brain Res (2005) 150:251-269.
2. Ploghaus A, Becerra L, Borras C, Borsook D: Neural circuitry underlying pain modulation: Expectation, hypnosis, placebo. Trends Cogn Sci (2003) 7(5):197-200.
3. Fillingim RB, Price DD: What is controlled for in placebo-controlled trials? Mayo Clin Proc (2005) 80(9): 1119-1121.
4. Tfelt-Hansen P, Henry P, Mulder LJ, Schaeldewaert RG, Schoenen J, Chazot G: The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet (1995) 346(8980): 923-926.
5. Henry P, Hiesse-provost O, Dillenschneider A, Ganry H, Insuaty J: Efficacy and tolerance of an effervescent aspirin-metoclopramide combination in the treatment of a migraine attack. Presse Med (1995) 24(5):254-258.
6. Diener HC: Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. Cephalalgia (1999) 19(6):581-588.
7. Bendtsen L, Mattsson P, Zwart JA, Lipton RB: Placebo response in clinical randomized trials of analgesics in migraine. Cephalalgia (2003) 23(7):487-490.
8. Tfelt-Hansen P, Block G, Dahlöf C, Diener HC, Ferrari MD, Goadsby PJ, Guidetti V, Jones B, Lipton RB, Massiou H, Meinert C et al: Guidelines for controlled trials of drugs in migraine: Second edition. Cephalalgia (2000) 20(9):765-786.
9. 1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet (2001) 358(9294): 1668-1675.
10. Ferrari MD: Efficacy and tolerability of oral triptans: A meta-analysis. In: The Triptans: Novel Drugs in Migraine. Olesen J, Ferrari MD, Humphrey PPA (Eds), Oxford University Press, Oxford, UK (2001).
11. Macedo A, Farre M, Banos JE: A meta-analysis of the placebo response in acute migraine and how this response may be influenced by some of the characteristics of clinical trials. Eur J Clin Pharmacol (2006) 62(3):161-172.
12. Holroyd KA, Penzien DB, Cordingley GE: Propranolol in the management of recurrent migraine: A meta-analytic review. Headache (1991) 31(5):333-340.
13. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, Rapoport AM, Silber CJ, Deaton RL: Migraine prophylaxis with divalproex. Arch Neurol (1995) 52(3):281-286.
14. Klapper J: Divalproex sodium in migraine prophylaxis: A dose-controlled study. Cephalalgia (1997) 17(2):103-108.
15. Peikert A, Wilimzig C, Köhne-Volland R: Prophylaxis of migraine with oral magnesium: Results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia (1996) 16(4):257-263.
16. van de Ven LL, Franke CL, Koehler PJ: Prophylactic treatment of migraine with bisoprolol: A placebo-controlled study. Cephalalgia (1997) 17(5):596-599.
17. Diener H, Krupp P, Schmitt T, Steitz G, Milde K, Freytag S: Cyclandelate in the prophylaxis of migraine: A placebo-controlled study. Cephalalgia (2001) 21(1):66-70.
18. Macedo A, Banos JE, Farre M: Placebo response in the prophylaxis of migraine: A meta-analysis. Eur J Pain (2008) 12(1):68-75.
19. Linde K, Streng A, Jurgens S, Hoppe A, Brinkhaus B, Witt C, Wagenpfeil S, Pfaffenrath V, Hammes MG, Weidenhammer W, Willich SN et al: Acupuncture for patients with migraine: A randomized controlled trial. JAMA (2005) 293(17):2118-2125. (Pubitemid 40617064)
20. Diener HC, Kronfeld K, Boewing G, Lungenhausen M, Maier C, Molsberger A, Tegenthoff M, Trampisch HJ, Zenz M, Meinert R: Efficacy of acupuncture for the prophylaxis of migraine: A multicentre randomised controlled clinical trial. Lancet Neurol (2006) 5(4):310-316.
21. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF: OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia (2010):doi:10.1177/033310241036 4677.
22. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF: OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache (2010) 50(6):921-936.
23. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF: OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia (2010):doi:10.1177/033310241036 4676.
24. Mathew NT, Kailasam J, Meadors L: Predictors of response to botulinum toxin type a (BoNTA) in chronic daily headache. Headache (2008) 48(2):194-200.
25. Freitag FG, Diamond S, Diamond M, Urban G: Botulinum toxin type a in the treatment of chronic migraine without medication overuse. Headache (2008) 48(2):201-209.
26. Blumenfeld AM, Schim JD, Chippendale TJ: Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache (2008) 48(2): 210-220.
27. Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM: Botulinum toxin type A prophylactic treatment of episodic migraine: A randomized, double-blind, placebo-controlled exploratory study. Headache (2007) 47(4):486-499.
28. de Craen AJ, Tijssen JG, de Gans J, Kleijnen J: Placebo effect in the acute treatment of migraine: Subcutaneous placebos are better than oral placebos. J Neurol (2000) 247(3):183-188.
29. Kaptchuk TJ, Stason WB, Davis RB, Legedza AR, Schnyer RN, Kerr CE, Stone DA, Nam BH, Kirsch I, Goldman RH: Sham device v inert pill: Randomised controlled trial of two placebo treatments. BMJ (2006) 332(7538):391-397.
30. Geraud G, Olesen J, Pfaffenrath V, Tfelt-Hansen P, Zupping R, Diener HC, Sweet R: Comparison of the efficacy of zolmitriptan and sumatriptan: Issues in migraine trial design. Cephalalgia (2000) 20(1):30-38.
31. Diener HC, Tfelt-Hansen P, Dahlöf C, Lainez JM, Sandrini M, Wang S-J, Neto W, Vijapurkar U, Doyle A, Jacobs D: Topiramate in migraine prophylaxis: Results from a placebo-controlled trial with propranolol as an active control. J Neurol (2004) 251(8):943-950.
32. Brandes J, Saper J, Diamond M, Couch J, Lewis D, Schmitt J, Neto W, Schwabe S, Jacobs D: Topiramate for migraine prevention: A randomized controlled trial. JAMA (2004) 291(8):965-973. (Pubitemid 38543754)
33. Bussone G, Diener H, Pfeil J, Schwalen S: Topiramate 100 mg/day in migraine prevention: A pooled analysis of double-blind randomised controlled trials. Int J Clin Pract (2005) 59(8):961-968.
34. Silberstein SD, Neto W, Schmitt J, Jacobs D: Topiramate in migraine prevention: Results of a large controlled trial. Arch Neurol (2004) 61(4):490-495. (Pubitemid 38923736)
35. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C: Botulinum toxin type A (Botox) for the prophylactic treatment of chronic daily headache: A randomized, doubleblind, placebo-controlled trial. Headache (2005) 45(4):293-307. (Pubitemid 40530193)
36. Silberstein SD, Gobel H, Jensen R, Elkind AH, Degryse R, Walcott JM, Turkel C: Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: A multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia (2006) 26(7):790-800.
37. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L: Topiramate in the treatment of chronic migraine. Cephalalgia (2003) 23(8):820-824.
38. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ: Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia (2007) 27(7):814-823.
39. Mathew N, Hettiarachchi J, Alderman J: Tolerability and safety of eletriptan in the treatment of migraine: A comprehensive review. Headache (2003) 43(9):962-974.
40. Diener HC: Eletriptan in migraine. Expert Rev Neurother (2005) 5(1):43-53.
41. Goadsby PJ, Lipton RB: Newer triptans: Emphasis on rizatriptan. Neurology (2000) 55(9 Suppl 2):S1-S2.
42. Loder E, Goldstein R, Biondi D: Placebo effects in oral triptan trials: The scientific and ethical rationale for continued use of placebo controls. Cephalalgia (2005) 25(2): 124-131.
43. Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S: Practice parameter: Pharmacological treatment of migraine headache in children and adolescents: Report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology (2004) 63(12):2215-2224. (Pubitemid 40024327)
44. Visser WH, Winner P, Strohmaier K, Klipfel M, Peng Y, McCarroll K, Cady R, Lewis D, Nett R: Rizatriptan 5 mg for the acute treatment of migraine in adolescents: Results from a double-blind, single-attack study and two open-label, multiple-attack studies. Headache (2004) 44(9):891-899.
45. Winner P, Lewis D, Visser H, Jiang K, Ahrens S, Evans JK: Rizatriptan 5 mg for the acute treatment of migraine in adolescents: A randomized, double-blind, placebo-controlled study. Headache (2002) 42(1):49-55.
46. Ahonen K, Hamalainen ML, Eerola M, Hoppu K: A randomized trial of rizatriptan in migraine attacks in children. Neurology (2006) 67(7):1135-1140.
47. Lewis SW, Winner P, Wasiewski W: The placebo responder rate in children and adolescents. Headache (2005) 45(3):232-239.
48. Evers S, Rahmann A, Kraemer C, Kurlemann G, Debus O, Husstedt IW, Frese A: Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology (2006) 67(3):497-499.
49. Winner P, Linder SL, Lipton RB, Almas M, Parsons B, Pitman V: Eletriptan for the acute treatment of migraine in adolescents: Results of a double-blind, placebo-controlled trial. Headache (2007) 47(4):511-518.
50. Evers S, Marziniak M, Frese A, Gralow I: Placebo efficacy in childhood and adolescence migraine: An analysis of double-blind and placebo-controlled studies. Cephalalgia (2009) 29(4):436-444.
51. Geraud G, Lanteri-Minet M, Lucas C, Valade D: French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther (2004) 26(8):1305-1318.